Report
AstraZeneca's experimental stomach cancer drug doubled survival time in late-stage trial
Bloomberg reports patients whose cancer had spread lived five months longer on sone-ve than on chemotherapy and other cancer drugs.
TLDR
Bloomberg reports that AstraZeneca's experimental drug sone-ve doubled survival time in a late-stage trial. Patients whose stomach cancer had spread despite other treatments lived five months longer than those receiving chemotherapy and other cancer drugs. Reuters reports the patients had received at least two prior treatments and lived longer than analysts expected.
Combined views
77.3K
7 Sources, first seen ago
